Other: Questionnaires ( DrugBank: - )

5 diseases

6. パーキンソン病

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03407378 (ClinicalTrials.gov)	June 26, 2018	15/1/2018	A Study to Investigate a New Treatment in Patients With Parkinson's Disease	A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease	Parkinson Disease	Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment	Tools4Patient	NULL	Completed	35 Years	N/A	All	110	Phase 1/Phase 2	United States;Belgium;France

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03983720 (ClinicalTrials.gov)	January 21, 2020	7/6/2019	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Sclerosis, Multiple	Other: Evaluation of degree chronic fatigue.;Other: Questionnaires;Biological: Blood sample;Other: Cardiopulmonary evaluation;Device: Capacity of muscular oxygen extraction;Device: Sleep assessment;Device: Metabolic fatigue;Other: Neuromuscular evaluation	Centre Hospitalier Universitaire de Saint Etienne	NULL	Recruiting	18 Years	70 Years	All	60	Phase 2	France

臨床試験数 : 128 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03892785 (ClinicalTrials.gov)	January 27, 2020	26/3/2019	MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial	MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial	Giant Cell Arteritis	Drug: Prednisone treatment;Drug: Tocilizumab treatment;Drug: Methotrexate treatment;Other: Questionnaires;Biological: Blood samples	Centre Hospitalier Universitaire Dijon	NULL	Recruiting	50 Years	N/A	All	200	Phase 3	France
2	NCT03711448 (ClinicalTrials.gov)	January 7, 2019	15/10/2018	Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis	Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis	Patients Relapsing Refractory Giant Cell Arteritis	Drug: prednisone treatment;Drug: prednisone and ustekinumab treatment;Other: questionnaires;Biological: Blood samples	Centre Hospitalier Universitaire Dijon	NULL	Recruiting	50 Years	N/A	All	38	Phase 2	France

臨床試験数 : 282 / 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02931513 (ClinicalTrials.gov)	September 2016	11/10/2016	sCD163 in PBC Patients - Assessment of Treatment Response	Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Treatment Response to UDCA	Primary Biliary Cirrhosis;Liver Inflammation;Ursodeoxycholic Acid	Other: Blood samples;Device: Fibroscan;Other: Questionnaires;Biological: Liver biopsy	University of Aarhus	NULL	Recruiting	18 Years	N/A	All	40		Denmark

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02859675 (ClinicalTrials.gov)	October 7, 2013	28/7/2016	Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease	Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease	Crohn's Disease;Olfactogustatory Perception	Other: triangular test;Biological: blood sampling;Other: Questionnaires	Centre Hospitalier Universitaire Dijon	NULL	Recruiting	18 Years	60 Years	Female	75		France
2	NCT02504255 (ClinicalTrials.gov)	April 2011	20/7/2015	Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease	Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease : A Multicenter Cohort	Crohn Disease	Biological: Biological samplings;Other: Questionnaires	Hospices Civils de Lyon	NULL	Completed	18 Years	N/A	Both	144		France